Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 71 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End-Stage Renal Disease Patients on Hemodialysis Clear all
Not yet recruiting Phase 1Phase 2 Interventional

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

NCT06609343
View directory record Official record
Conditions
End Stage Renal Disease, Fatigue
Interventions
Bupropion Hydrochloride 150 MG
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
25 Years to 74 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Not applicable Interventional

A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients

NCT00308295
View directory record Official record
Conditions
End-Stage Renal Disease Patients on Hemodialysis
Interventions
Fish oil capsules, matched placebo capsules
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 82 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2007 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).

NCT04094064
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitor
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Phase 1 Interventional

Effects of Hemodialysis on the Sleep/Wake Cycle

NCT00460863
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
using cool versus warm dialysate during hemodialysis
Procedure
Lead sponsor
Emory University
Other
Eligibility
21 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 10, 2026, 9:30 AM EDT
Completed No phase listed Observational

Oxidative Stress and Hemodialysis Access Failure

NCT00410449
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Alpha tocopherol
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597584
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin alfa or Epoetin beta
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • McGehee, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 10, 2026, 9:30 AM EDT
Completed No phase listed Observational

Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis

NCT00340119
View directory record Official record
Conditions
End Stage Renal Disease, ESRD
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Not applicable Interventional

Pomegranate and Hemodialysis Pilot Trial

NCT01562340
View directory record Official record
Conditions
End Stage Renal Disease, Cardiovascular Disease, Inflammation
Interventions
Pomegranate juice, Pomegranate fruit extract
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Not applicable Interventional

Dietary Protein Requirements in Hemodialysis Patients

NCT02194114
View directory record Official record
Conditions
Chronic Renal Failure, End-Stage Renal Disease
Interventions
Protein Diet
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
25 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 10, 2026, 9:30 AM EDT
Withdrawn Phase 4 Interventional

Spironolactone Safety in Dialysis Patients

NCT00328809
View directory record Official record
Conditions
End Stage Renal Disease, Congestive Heart Failure
Interventions
spironolactone
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Triferic Pediatric Pharmacokinetic Protocol

NCT02595437
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Loma Linda, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 10, 2026, 9:30 AM EDT
Terminated Phase 3 Interventional Results available

The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis

NCT00503698
View directory record Official record
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
somatropin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
209
States / cities
Alexander City, Alabama • Birmingham, Alabama • Madison, Alabama + 177 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Not applicable Interventional Results available

Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial)

NCT02933151
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Nutritional Supplement
Dietary Supplement
Lead sponsor
Dialysis Clinic, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Not applicable Interventional

The Effects of Cool Dialysate on the Sleep/Wake Cycle in Patients on Chronic Hemodialysis - "The Sleep Cool Study"

NCT00218790
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Cool Dialysate
Procedure
Lead sponsor
Emory University
Other
Eligibility
21 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 10, 2026, 9:30 AM EDT
Withdrawn No phase listed Observational

Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis

NCT02164175
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
HeRO Graft implant for dialysis access
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Dallas, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Not applicable Interventional

Randomized Study of Recombinant Human Growth Hormone in Patients on Chronic Hemodialysis or Peritoneal Dialysis

NCT00004429
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
growth hormone
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

NCT01764854
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD
Interventions
AZD1722 (in-patient), Placebo (in-patient), AZD1722 (out-patient), Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Tempe, Arizona • Denver, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Not applicable Interventional Results available

Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis

NCT03301740
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
UF profiling during HD, Conventional HD
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Carrboro, North Carolina • Siler City, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Phase 4 Interventional Results available

Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5

NCT02392208
View directory record Official record
Conditions
End-Stage Renal Disease, Stage 5 Chronic Kidney Disease
Interventions
Telavancin, Pharmacokinetic Blood Sampling
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 10, 2026, 9:30 AM EDT
Terminated Phase 4 Interventional Results available

Bupropion for Depression in ESRD Patients on Hemodialysis

NCT02238977
View directory record Official record
Conditions
Major Depression, End Stage Renal Disease
Interventions
Fluoxetine, Bupropion
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
30 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Not applicable Interventional Results available

Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis

NCT04985383
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
AKST1210 S-15 at 250 mL/min, AKST1210 S-15 at 450 mL/min, AKST1210 S-25 at 250 mL/min, AKST1210 S-25 at 450 mL/min, AKST1210 S-35 at 250 mL/min, AKST1210 S-35 at 450 mL/min
Device
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Granada Hills, California • Northridge, California • Gallup, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 10, 2026, 9:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

NCT03087942
View directory record Official record
Conditions
Renal Insufficiency
Interventions
QAW039, QAW39A, QAW39A2107
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 10, 2026, 9:30 AM EDT
Not listed No phase listed Observational

Impact of IDPN on Nutrition Markers in Patients Receiving ICHD

NCT05439174
View directory record Official record
Conditions
End-stage Renal Disease, Malnutrition; Protein
Interventions
Intradialytic Parenteral Nutrition
Other
Lead sponsor
Patient Care America
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 10, 2026, 9:30 AM EDT